This trial is studying a drug to see if it is safe and effective for patients with non-dialysis chronic kidney disease.
2 Primary · 15 Secondary · Reporting Duration: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose
Experimental Treatment
Non-Treatment Group
88 Total Participants · 4 Treatment Groups
Primary Treatment: AND017 · Has Placebo Group · Phase 2
Age 20 - 74 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:North Carolina | 100.0% |
65+ | 100.0% |
Metrolina Nephrology Associates | 100.0% |
Did not meet criteria | 50.0% |
Met criteria | 50.0% |